A sporadic Alzheimer's blood-brain barrier model for developing ultrasound-mediated delivery of Aducanumab and anti-Tau antibodies.

Notably, the delivery of RNF5 was significantly increased in APOE3 (1.15 ± 0.06 fold, mean ± SE, P = 0.0295) with APOE4 iBECs demonstrating a strong trend toward an increase in RNF5 delivery (1.26 ± 0.12 fold, mean ± SE, P = 0.0501) when treated with FUS +MB as compared to UT (Figure 3 G).

also in 5,725 other papers